SCHEMBL3749697

SCHEMBL3749697

N=CCc1ccc(O)cc1O

nearest known ligand 0.60

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TYR P14679 6/20 0.60
ALOX5 P09917 3/20 0.48
MEN1 O00255 2/20 0.46
MAPT P10636 2/20 0.46
KMT2A Q03164 2/20 0.46
TP53 P04637 1/20 0.46
CYP3A4 P08684 1/20 0.46
ALOX15 P16050 1/20 0.46
TSHR P16473 1/20 0.46
HTT P42858 1/20 0.46
TDP1 Q9NUW8 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21802278 0.81 TYR (0.65) TYRALOX5MEN1MAPTKMT2A
SCHEMBL21225589 0.80 CA3 (0.48) TYR
SCHEMBL933119 0.80 TYR (0.58) TYRALOX5MEN1MAPTKMT2A
SCHEMBL69697 0.80 TYR (0.58) TYRALOX5MEN1MAPTKMT2A
SCHEMBL30513627 0.80 TYR (0.58) TYRALOX5MEN1MAPTKMT2A
SCHEMBL3749696 0.80 TYR (0.58) TYRALOX5MEN1MAPTKMT2A
SCHEMBL2361005 0.78 TYR (0.56) TYRALOX5MEN1MAPTKMT2A
SCHEMBL21802276 0.78 TYR (0.61) TYRALOX5MEN1MAPTKMT2A
SCHEMBL8698637 0.77 TYR (0.54) TYRALOX5MEN1KMT2ACYP3A4
SCHEMBL3934466 0.77 TYR (0.54) TYRALOX5MEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795163-B2 Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same CHECKMATE THERAPEUTICS INC. 2023-10-24 US disclosed
US-20230270692-A1 COMPOUNDS FOR CHRONIC DISORDERS PILLAI UNIVERSAL LLC 2023-08-31 US disclosed
US-20230270692-A1 COMPOUNDS FOR CHRONIC DISORDERS PILLAI UNIVERSAL LLC 2023-08-31 US disclosed
US-11078195-B2 Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same CHECKMATE THERAPEUTICS INC. 2021-08-03 US disclosed
US-20210171513-A1 NOVEL COMPOUND FOR INHIBITING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE AND COMPOSITION CONTAINING SAME CHECKMATE THERAPEUTICS INC. (KR) 2021-06-10 US disclosed
CN-108779104-B Novel compounds for inhibiting nicotinamide phosphoribosyltransferase and compositions containing same 将军治疗有限公司 2021-04-13 CN disclosed
US-20200247795-A1 NOVEL COMPOUND FOR INHIBITING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE AND COMPOSITION CONTAINING SAME CHECKMATE THERAPEUTICS INC. (KR) 2020-08-06 US disclosed
EP-3431472-A2 NOVEL COMPOUND FOR INHIBITING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE AND COMPOSITION CONTAINING SAME Industry-Academic Cooperation Foundation Yonsei University (KR) 2019-01-23 EP disclosed
US-7834210-B2 Hair loss prevention by natural amino acid and peptide complexes BIODERM RESEARCH (US) 2010-11-16 US disclosed
US-20090253668-A1 Hair Loss Prevention by Natural Amino Acid and Peptide Complexes BIODERM RESEARCH (US) 2009-10-08 US disclosed
US-7572933-B2 Skin and hair restoration by natural amino acid peptide complexes BIODERM RESEARCH (US) 2009-08-11 US disclosed
US-20080287536-A1 Skin and Hair Restoration by Natural Amino Acid and Peptide Crown Complexes BIODERM RESEARCH (US) 2008-11-20 US disclosed
US-7427690-B2 Multifunction “crown complexes” from amino acids and peptides for skin and hair restoration BIODERM RESEARCH (US) 2008-09-23 US disclosed
US-20070099886-A1 Multifunction \"Crown Complexes\" from Amino Acids and Peptides for Skin and Hair Restoration BIODERM RESEARCH (US) 2007-05-03 US disclosed
EP-0522000-A1 5-LIPOXYGENASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1993-01-13 EP disclosed
WO-1991014674-A2 5-LIPOXYGENASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1991-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11078195-B2 Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same NAMPT, NAPRT, NNT TYR 1849/4885ALOX5 1786/4885MEN1 1469/4885
US-20200247795-A1 NOVEL COMPOUND FOR INHIBITING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE AND COMPOSITION CONTAINING SAME NAMPT, NAPRT, NNMT TYR 2702/4885ALOX5 2652/4885MEN1 2480/4885
US-20080287536-A1 Skin and Hair Restoration by Natural Amino Acid and Peptide Crown Complexes MMP17, MC1R, TYR TYR 3/4885ALOX5 1100/4885MEN1 4115/4885
US-20210171513-A1 NOVEL COMPOUND FOR INHIBITING NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE AND COMPOSITION CONTAINING SAME NAMPT, NAPRT, NNMT TYR 2702/4885ALOX5 2652/4885MEN1 2480/4885
US-20090253668-A1 Hair Loss Prevention by Natural Amino Acid and Peptide Complexes MMP1, MMP17, MMP13 TYR 91/4885ALOX5 1254/4885MEN1 3386/4885
US-20230270692-A1 COMPOUNDS FOR CHRONIC DISORDERS FABP6, FABP1, CFTR TYR 2237/4885ALOX5 236/4885MEN1 3763/4885
US-11795163-B2 Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same NAMPT, NAPRT, NNT TYR 1849/4885ALOX5 1786/4885MEN1 1469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.